



To: Jai Medical Providers
From: ProCare Rx
Date: February 1, 2018
Subject: 1st Quarter Important Announcements

Effective immediately, the following product has been added to the Jai formulary with prior authorization required:

- **Vosevi**

- Indication: Chronic Hepatitis C
- Criteria:
 - Must follow the clinical criteria as set by the Maryland Department of Health.
 - Prior DAA experience with an NS5A inhibitor (all genotypes) or sofosbuvir (genotypes 1a, 3)
 - Prior to requesting/initiating therapy with this agent in a patient with cirrhosis (stage F4 by Metavir), documentation of Child-Pugh status of A is required.
 - Prior to requesting/initiating therapy with this agent, documentation of eGFR \geq 30mL/min is required for approval.

Providers can contact ProCare's Prior-Authorization Department at 800-555-8513 for assistance with PA requests or questions regarding clinical guidelines. Our PA Department is available Monday through Friday from 8:30 am-5:30 pm EST. For assistance with PA requests during non-business hours please contact our 24 hour customer service department at 800-213-5640.